Y-mAbs Therapeutics, Inc. (YMAB) Financial Statements (2024 and earlier)

Company Profile

Business Address 230 PARK AVENUE
NEW YORK, NY 10169
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments105,762181,564114,634207,136147,840
Cash and cash equivalents105,762181,564114,634207,136147,840
Restricted cash and investments     31
Receivables12,5317,712   
Inventory, net of allowances, customer advances and progress billings6,7025,512   
Inventory6,7025,512   
Other current assets5,4527,4737,7294,8193,661
Total current assets:130,447202,261122,363211,955151,532
Noncurrent Assets
Operating lease, right-of-use asset1,7393,8424,5691,989
Property, plant and equipment6041,8471,8252,052205
Intangible assets, net (including goodwill)2,9861,663   
Intangible assets, net (excluding goodwill)2,9861,663   
Other noncurrent assets5,6803,1703,290370187
Total noncurrent assets:11,00910,5229,6844,411392
TOTAL ASSETS:141,456212,783132,047216,366151,924
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities27,41626,09217,56913,0709,123
Accounts payable14,17513,5529,3728,5205,872
Accrued liabilities13,24112,5408,1974,5503,251
Debt    516 
Other undisclosed current liabilities8681,7831,966  
Total current liabilities:28,28427,87519,53513,5869,123
Noncurrent Liabilities
Long-term debt and lease obligation:  1,8512,0131,714 
Liabilities, other than long-term debt1,7018511,968242224
Other liabilities8028511,968242224
Operating lease, liability8991,8512,0131,714
Other undisclosed noncurrent liabilities2,2502,1002,6951,9212,050
Total noncurrent liabilities:3,9514,8026,6763,8772,274
Total liabilities:32,23532,67726,21117,46311,397
Equity
Equity, attributable to parent109,221180,106105,836198,903140,527
Common stock44443
Additional paid in capital543,929519,206391,558364,712225,352
Accumulated other comprehensive income (loss)1,3311,371(526)507
Accumulated deficit(436,043)(340,475)(285,200)(165,863)(84,835)
Total equity:109,221180,106105,836198,903140,527
TOTAL LIABILITIES AND EQUITY:141,456212,783132,047216,366151,924

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues65,26734,89720,750  
Cost of revenue(7,567)(2,514)   
Cost of goods and services sold(7,467)(2,304)   
Gross profit:57,70032,38320,750  
Operating expenses(152,511)(147,816)(140,685)(83,004)(43,230)
Operating loss:(94,811)(115,433)(119,935)(83,004)(43,230)
Nonoperating income (expense)(797)58,2611,1741,933(141)
Investment income, nonoperating  62,010   
Gain (loss), foreign currency transaction, before tax(40)(1,897)576(43)(97)
Other nonoperating income (expense)(757)(1,852)5981,976(44)
Loss from continuing operations before equity method investments, income taxes:(95,608)(57,172)(118,761)(81,071)(43,371)
Other undisclosed income (loss) from continuing operations before income taxes401,897(576)4397
Loss from continuing operations before income taxes:(95,568)(55,275)(119,337)(81,028)(43,274)
Income tax expense     
Loss from continuing operations:(95,568)(55,275)(119,337)(81,028)(43,274)
Loss before gain (loss) on sale of properties:(55,275)(119,337)(81,028)(43,274)
Net loss available to common stockholders, diluted:(95,568)(55,275)(119,337)(81,028)(43,274)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(95,568)(55,275)(119,337)(81,028)(43,274)
Comprehensive loss:(95,568)(55,275)(119,337)(81,028)(43,274)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(40)1,897(576)43175
Comprehensive loss, net of tax, attributable to parent:(95,608)(53,378)(119,913)(80,985)(43,099)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: